Pfizer Seeks Full FDA Approval for Paxlovid Amid Upcoming Advisory Committee Meeting

U.S. Biopharmaceutical Industry Media Endpoints News Reports: Pfizer Seeks Full FDA Approval for Its COVID-19 Oral Drug, Paxlovid (Nirmatrelvir/Ritonavir). The Matter Will Be Discussed in Detail at the FDA Advisory Committee Meeting in March This Year. This Suggests That the Usage of Paxlovid May Be Expanded Again and Could Potentially Be Fully Utilized for High-Risk COVID-19 Patients. (The Paper)